|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Forty-nine cases (41 patients) with CD8+ CTCLs/LPDs were examined, including CD8+ mycosis fungoides (MF) (n = 14), aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (AETCL) (n = 8), subcutaneous panniculitis-like T-cell lymphoma (SPTCL) (n = 7), CD30+ LPDs (n = 6), primary cutaneous γδ T-cell lymphoma (GDTCL) (n = 6), and others (n = 8).
|
31355940 |
2020 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary cutaneous anaplastic large cell lymphoma (pc-ALCL) is a CD30+ subtype of cutaneous T-cell lymphoma.
|
31141854 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 75-year-old patient presented with a multiresistant CD30+ T-cell cutaneous lymphoma disseminated throughout the whole skin surface.
|
31303340 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD30 is promising target as it is universally expressed in virtually all classical Hodgkin lymphomas, anaplastic large cell lymphomas, and in a proportion of other lymphoma types, including cutaneous T cell lymphomas and diffuse large B cell lymphomas.
|
30841880 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas.
|
30630983 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most frequent CTCL subtypes, in decreasing order of prevalence, were mycosis fungoides (MF), including its variants (75.7%); CD30+ primary cutaneous lymphoproliferative disorders (7.2%); and Sézary syndrome (SS) (3.1%).
|
30294921 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting agent monomethylauristatin E. The utility of brentuximab vedotin has been explored in a number of diseases, with a recent focus on T-cell lymphoma, particularly systemic anaplastic large-cell lymphoma (sALCL) and cutaneous T-cell lymphoma (CTCL), as well as other peripheral T-cell lymphoma (PTCL) histologies.
|
30526166 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on the few cases reported herein, one might suggest that the prognosis mirrors that seen in other forms of cutaneous T cell lymphoma with mature small cell dominant infiltrates exhibiting an indolent pattern while a CD30 negative large cell T cell lymphoma would be expected to demonstrate an aggressive clinical course.
|
30572149 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ LPD) are the second most common form of cutaneous T-cell lymphoma.
|
29719017 |
2018 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we report that enhancer of zeste homolog 2 (EZH2), the catalytic subunit of polycomb repressive complex 2 that mediates histone H3 lysine 27 trimethylation, is overexpressed in CD30+ anaplastic cells in primary cutaneous anaplastic T-cell lymphoma and large-cell transformed cutaneous T-cell lymphoma.
|
29248547 |
2018 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
We reviewed the clinical and pathologic features of 12 patients (male-female ratio, 7:5; median age, 61 years) with an atypical ELR histologically mimicking a primary cutaneous T-cell lymphoma such as Sézary syndrome or CD30+ T-cell lymphoproliferative disorder.
|
29107664 |
2018 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nine patients were enrolled in a physician-initiated, open-label, single-center, phase 2 clinical trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and LyP from 2011 to 2013.
|
28980004 |
2017 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with a physician's choice of either methotrexate or bexarotene, the CD30-directed antibody-drug conjugate brentuximab vedotin led to significantly superior clinical responses in patients with cutaneous T-cell lymphomas, according to the results of the international phase III ALCANZA trial.
|
28119332 |
2017 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Histopathology findings confirmed a diagnosis of pcALCL, which is a subtype of cutaneous T-cell lymphoma characterized by the presence of CD30+ T cells.
|
28337783 |
2017 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to assess efficacy and safety of brentuximab vedotin versus conventional therapy for previously treated patients with CD30-positive cutaneous T-cell lymphomas.
|
28600132 |
2017 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
BV provides an effective targeted therapy for CD30-expressing cutaneous lymphomas and welcome addition to our anti-CTCL armory.
|
28805086 |
2017 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cutaneous T-cell lymphomas (CTCL) are skin malignancies including mycosis fungoides (MF) and CD30(+) lymphoproliferative disorders (LPD).
|
27345620 |
2016 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma (CTCL), followed by CD30+ lymphoproliferative disorders, including lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL).
|
26266670 |
2016 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
After bone marrow transplantation, the transformed CD30 cutaneous T-cell lymphoma recurred as a transformed CD30 plaque MF.
|
25548993 |
2015 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cutaneous CD30(+) lymphoproliferative disease (CD30(+)LPD), characterized by the presence of CD30(+) anaplastic large T cells, comprises the second most common group of cutaneous T-cell lymphoma (CTCL).
|
24747435 |
2014 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our in situ analysis of MF and CD30(+)d tissue samples correlates well with previous functional studies of CTCL cell lines and leukemic blood.
|
22884443 |
2012 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30+ lymphoproliferative disorders of the skin represent a well-defined spectrum of primary cutaneous T-cell lymphomas.
|
23149700 |
2012 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One mycosis fungoides and one pleomorphic CTCL harbored a KRAS(G13D) mutation; one Sézary syndrome and one CD30(+) CTCL harbored a NRAS(Q61K) amino acid change.
|
21209378 |
2011 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases.
|
19812605 |
2010 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inactivation of the CDKN2A-CDKN2B locus has been reported in the most frequent subtypes of cutaneous T-cell lymphomas (CTCLs), mycosis fungoides, Sézary syndrome (SS) and CD30+ cutaneous anaplastic large cell lymphoma.
|
20118908 |
2010 |